24/7 Market News Snapshot 21 August, 2024 – Bio-Path Holdings Inc (NASDAQ:BPTH)

August 21, 2024

DENVER, Colo., 21 August, 2024 (247marketnews.com) – (NASDAQ:BPTH) are discussed in this article.
Bio-Path Holdings Inc. is navigating a challenging trading environment, currently seeing its stock priced at $2.096 during pre-market activity, reflecting no change from the previous session’s close of $1.480. This stagnation comes after a notable rally that generated increased interest, evidenced by a trading volume of 1.90 million shares. Investors may be showing caution amid potential profit-taking, and key technical indicators, including moving averages, are being monitored to identify support and resistance levels. Should the momentum sustain, a breakthrough above $2.20 may signal further gains; however, a dip below the $2 mark could prompt traders to exercise caution.

In addition to the market fluctuations, Bio-Path Holdings has reported significant advancements in its clinical trials, particularly with BP1001-A for solid tumors. Recent updates from the Phase 1/1b trial indicate promising results, including tumor regression in a heavily pretreated patient with gynecologic cancer who has shown a 15% reduction in her primary tumor after six cycles of treatment at a higher dose of 90 mg/m². These outcomes underline the potential of BP1001-A to offer a novel therapeutic option for patients with limited treatment avenues.

Furthermore, a Phase 2 study concerning the triple combination of prexigebersen, venetoclax, and decitabine in Acute Myeloid Leukemia (AML) has also shown encouraging remissions. Notable responses have been observed in two older patients, who have sustained significant remissions over extended treatment periods, highlighting the therapy’s durability and effectiveness.

Peter H. Nielsen, President and CEO, emphasized the promise of the DNAbilize platform technology to enhance treatment protocols. As Bio-Path continues to develop its portfolio, the company remains focused on driving innovation to improve outcomes for cancer patients.

Related news for (BPTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.